Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Down 24.8% in February

Hoth Therapeutics, Inc. (NASDAQ:HOTH) was the recipient of a significant drop in short interest in February. As of February 28th, there was short interest totalling 174,100 shares, a drop of 24.8% from the February 13th total of 231,500 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average daily trading volume, of 8,460,000 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

HOTH has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Hoth Therapeutics in a research report on Thursday, January 23rd. D. Boral Capital reaffirmed a “buy” rating and set a $5.00 price target on shares of Hoth Therapeutics in a research note on Monday, March 10th.

Hedge Funds Weigh In On Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC bought a new position in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics as of its most recent SEC filing. Institutional investors own 7.08% of the company’s stock.

Hoth Therapeutics Stock Performance

HOTH stock opened at $1.06 on Wednesday. The company has a fifty day moving average price of $1.24 and a 200-day moving average price of $1.01. The company has a market capitalization of $7.32 million, a P/E ratio of -0.80 and a beta of 0.84. Hoth Therapeutics has a 52-week low of $0.58 and a 52-week high of $3.80.

Hoth Therapeutics Company Profile

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.